Metabolic & Body Composition
Tesamorelin
FDA-approved GHRH analog for the reduction of visceral abdominal fat in clinical populations with HIV. Potent and effective for central fat reduction.
Also known as: Egrifta · TH9507
Specifications
| Research area | Metabolic & Body Composition | ||
|---|---|---|---|
| Half-life | ~30 min | ||
| Molecular weight | 5136.0 Da | ||
| Amino acid residues | 44 | ||
| CAS number | 218949-48-9 | ||
| Formula | C₂₂₁H₃₆₆N₇₂O₆₇S | ||
| Sequence | trans-3-hexenoyl-GHRH(1-44)NH₂ (Tyr-Ala-Asp-Ala-Ile-Phe...44 aa) | ||
| Designation | trans-3-hexenoyl-Tyr¹-hGRF(1-44)NH₂ | ||
Pharmacokinetics
| Half-life | ~30 min | ||
|---|---|---|---|
| T-max | ~15 min | ||
| C-max | 2.9–3.5 ng/mL (2 mg SC) | ||
| Bioavailability | ~4% SC (peptide) | ||
| Route | Subcutaneous (research use) | ||
Receptor targets
| GHRH receptor | Pituitary agonist | ||
|---|---|---|---|
| Anterior pituitary somatotrophs | Endogenous GH release | ||
Signalling cascade
- GHRH-R binding
- Gαs activation
- cAMP ↑
- GH secretion
- Hepatic IGF-1 production
- Lipolysis (visceral fat)
Research areas
- Mechanism of action
- Synthetic analogue of endogenous GHRH(1-44) stabilized with trans-3-hexenoic acid at the N-terminus. Binds pituitary GHRH receptors to stimulate endogenous GH secretion and downstream IGF-1 production while preserving natural feedback regulation via somatostatin.
- Reported research ranges
- 2 mg subcutaneously once daily in the abdomen.
- Reported adverse effects
- Peripheral edema, arthralgia, myalgia, water retention, hyperglycemia in predisposed individuals.
- Storage and handling
- Refrigerate at 2–8 °C after reconstitution. Do not freeze.
Research focus
- Visceral adipose tissue metabolism and lipolysis
- IGF-1 axis activation and growth factor cascade
- Endocrine feedback regulation via somatostatin
- Lipodystrophy and metabolic dysfunction models
- Sustained GHRH receptor binding pharmacokinetics
Overview
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) that has been specifically designed to provide clean and repetitive pulses of growth hormone in cellular and rodent models. Its ability to induce controlled secretions of growth hormone allows researchers to examine various metabolic processes, particularly those related to fat metabolism.
Research on Tesamorelin focuses on its role in activating insulin-like growth factor 1 (IGF-1) and in endocrine feedback mechanisms. These studies are crucial for understanding how growth hormone is regulated in the body and how it influences metabolism, which may have significant implications in the research of metabolic disorders.
This material is published for scientific and educational reference. It is not medical advice, not a treatment recommendation, and not an offer to sell. Compounds discussed are for research and laboratory use only.
← All compounds